The North America Onychomycosis Market should witness market growth of 4.2% CAGR during the forecast period (2022-2028).
Onychomycosis can be brought on by a variety of fungi, including Fusarium and dermatophytes. Risk factors include athletes' foot or someother nail/footconditions,peripheral vascular disease,contact with those who have it,and a weakened immune system. Usually, based on the appearance, the diagnosis is speculated, and laboratory testing is used to confirm it. Numerous kinds of fungi that are present in the environmentcause fungus-related nail diseases. These germs can enter the nail through tiny holes in the skin around it or in the nail, inflicting an infection.
The most effective course of treatment for fungus nail infections is to begin early, frequently through oral administration of prescription antifungal medications. In extreme circumstances, a medical practitioner might fully remove the nail. However, the illness may take a few months to one year to clear up. Fungal skin infections can often occur with fungal nail infections. In addition, the fungal infection spreads from one location to another if it is not treated. Fungalinfections can recur even after therapy.
The prevalence of diabetes and the aging population in the region are the primary factors propelling the region's onychomycosis treatment demand. More than 3 million Canadians are diagnosed to be suffering from diabetes. Moreover, in 2016, the Census Bureau estimated that there were around 49.2million Americans who were 65 or older, with one-fourth of them residing in one of the three states of California, Florida, or Texas. Seven additional states - Georgia, Illinois, Michigan, and New York - make up another quarter of the population aged 65 and over. This supports the growth of the regional market.
The US market dominated the North America Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.9 Million by 2028. The Canada market is poised to grow at a CAGR of 6.5% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 5.6% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Onychomycosis can be brought on by a variety of fungi, including Fusarium and dermatophytes. Risk factors include athletes' foot or someother nail/footconditions,peripheral vascular disease,contact with those who have it,and a weakened immune system. Usually, based on the appearance, the diagnosis is speculated, and laboratory testing is used to confirm it. Numerous kinds of fungi that are present in the environmentcause fungus-related nail diseases. These germs can enter the nail through tiny holes in the skin around it or in the nail, inflicting an infection.
The most effective course of treatment for fungus nail infections is to begin early, frequently through oral administration of prescription antifungal medications. In extreme circumstances, a medical practitioner might fully remove the nail. However, the illness may take a few months to one year to clear up. Fungal skin infections can often occur with fungal nail infections. In addition, the fungal infection spreads from one location to another if it is not treated. Fungalinfections can recur even after therapy.
The prevalence of diabetes and the aging population in the region are the primary factors propelling the region's onychomycosis treatment demand. More than 3 million Canadians are diagnosed to be suffering from diabetes. Moreover, in 2016, the Census Bureau estimated that there were around 49.2million Americans who were 65 or older, with one-fourth of them residing in one of the three states of California, Florida, or Texas. Seven additional states - Georgia, Illinois, Michigan, and New York - make up another quarter of the population aged 65 and over. This supports the growth of the regional market.
The US market dominated the North America Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.9 Million by 2028. The Canada market is poised to grow at a CAGR of 6.5% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 5.6% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Scope of the Study
By Type
- Distal Subungual
- Proximal Subungual
- White Superficial
- Others
By Treatment
- Topical
- Oral
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Onychomycosis Market, by Type
1.4.2 North America Onychomycosis Market, by Treatment
1.4.3 North America Onychomycosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Onychomycosis Market by Type
3.1 North America Distal Subungual Market by Country
3.2 North America Proximal Subungual Market by Country
3.3 North America White Superficial Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Onychomycosis Market by Treatment
4.1 North America Topical Market by Country
4.2 North America Oral Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Onychomycosis Market by Country
5.1 US Onychomycosis Market
5.1.1 US Onychomycosis Market by Type
5.1.2 US Onychomycosis Market by Treatment
5.2 Canada Onychomycosis Market
5.2.1 Canada Onychomycosis Market by Type
5.2.2 Canada Onychomycosis Market by Treatment
5.3 Mexico Onychomycosis Market
5.3.1 Mexico Onychomycosis Market by Type
5.3.2 Mexico Onychomycosis Market by Treatment
5.4 Rest of North America Onychomycosis Market
5.4.1 Rest of North America Onychomycosis Market by Type
5.4.2 Rest of North America Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Companies Mentioned
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Methodology
LOADING...
